

Nivolumab + ipilimumab CheckMate142

PRELIMINARY SCORE

CURATIVE



NON-CURATIVE



ADJUSTMENTS

Quality of life



Not qualified for an ESMO-MCBS credit



Serious and disabling adverse effects



Other adjustments



Nivolumab + ipilimumab CheckMate142

SCORE

CURATIVE




Overall Survival / Disease-Free Survival / Pathological Complete Response

NON-CURATIVE



Overall Survival



Progression-Free Survival



Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate



Overall Response Rate / Duration of Response

Overall Survival / Disease-Free Survival / Pathological Complete Response

INFORMATION

Tumour type: Gastrointestinal Cancers

Therapeutic Indication: FDA: Treatment of adult patients with dMMR or MSI-H mCRC after prior fluoropyrimidine-based combination ChT. EMA: Nivolumab in combination with ipilimumab for the treatment adult patients with dMMR or MSI-H colorectal cancer after prior fluoropyrimidine based combination chemotherapy

Experimental Arm: Nivolumab + ipilimumab

Control Arm: Single arm



